It has been reported that GPS2 deletion activates AKT signaling to promote proliferation of triple-negative breast cancer cells (MDA-MB-231) [51], and it inhibits the proliferation of gastric cancer cells by increasing the ubiquitylation of the epidermal growth factor receptor (EGFR) [52]. The gene discussed is GPS2; the disease is triple-negative breast carcinoma.